The insurance industry should work with stakeholders in the emerging field of synthetic biology, in order to support the responsible development of new technologies and solutions, says a new report from Lloyd's and Imperial College London.
If you are already a subscriber
OR sign-up for a trial access here
Note that your comment may be edited or removed in the future, and that your comment may appear alongside the original article on websites other than this one.
Brought to you by